Bal Pharma Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bal Pharma Ltd is ₹ 75.6 as of 30 Apr 15:30 . The P/E Ratio of Bal Pharma Ltd changed from 16.8 on March 2021 to 18.4 on March 2025 . This represents a CAGR of 1.84% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Bal Pharma Ltd changed from ₹ 79.67 crore on March 2021 to ₹ 132.4 crore on March 2025 . This represents a CAGR of 10.69% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Bal Pharma Ltd for the Dec '25 is ₹ 88.02 crore as compare to the Sep '25 revenue of ₹ 75.14 crore. This represent the growth of 17.14% The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The ebitda of Bal Pharma Ltd for the Dec '25 is ₹ 9.87 crore as compare to the Sep '25 ebitda of ₹ 6.85 crore. This represent the growth of 44.09% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The net profit of Bal Pharma Ltd changed from ₹ 0.26 crore to ₹ 1.79 crore over 7 quarters. This represents a CAGR of 201.15% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The Dividend Payout of Bal Pharma Ltd changed from 16.29 % on March 2021 to 24.49 % on March 2025 . This represents a CAGR of 8.50% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Bal Pharma Ltd

Bal Pharma Limited (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 1987.
In March 1990, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc.
The company promotes its products through the common sales force of the group but proposes to induct its own soon.
It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Bal Pharma Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Bal Pharma Ltd or Medicamen Biotech Ltd?

Market cap of Bal Pharma Ltd is 120 Cr while Market cap of Medicamen Biotech Ltd is 343 Cr

What are the key factors driving the stock performance of Bal Pharma Ltd and Medicamen Biotech Ltd?

The stock performance of Bal Pharma Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bal Pharma Ltd and Medicamen Biotech Ltd?

As of May 3, 2026, the Bal Pharma Ltd stock price is INR ₹75.6. On the other hand, Medicamen Biotech Ltd stock price is INR ₹253.3.

How do dividend payouts of Bal Pharma Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Bal Pharma Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.